Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits

Mark E. Potter, Edward E. Partridge, Hugh M. Shingleton, Seng Jaw Soong, Robert Y. Kim, Kenneth D. Hatch, J. Maxwell Austin

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

Original languageEnglish (US)
Pages (from-to)314-318
Number of pages5
JournalGynecologic oncology
Volume32
Issue number3
DOIs
StatePublished - Mar 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits'. Together they form a unique fingerprint.

  • Cite this

    Potter, M. E., Partridge, E. E., Shingleton, H. M., Soong, S. J., Kim, R. Y., Hatch, K. D., & Austin, J. M. (1989). Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits. Gynecologic oncology, 32(3), 314-318. https://doi.org/10.1016/0090-8258(89)90631-8